Newron Pharmaceuticals S.p.A.
Biopharmaceutical company developing therapies for nervous system disorders and pain.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Manufacturing
Description
Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-13 02:00 |
EQS-News: Newron reports compelling additional data documenting the efficacy of…
|
English | 15.7 KB | ||
| 2024-05-13 02:00 |
EQS-News: Newron veröffentlicht überzeugende zusätzliche Daten, welche die Wirk…
|
German | 16.6 KB | ||
| 2024-05-13 02:00 |
EQS-Adhoc: Newron veröffentlicht zusätzliche Daten, welche die Wirksamkeit v…
|
German | 14.3 KB | ||
| 2024-04-30 02:00 |
EQS-News: Newron announces positive top-line results from potentially pivotal …
|
English | 14.3 KB | ||
| 2024-04-30 02:00 |
EQS-News: Newron: Positive Topline-Ergebnisse der potenziell zulassungsrelevant…
|
German | 16.4 KB | ||
| 2024-04-30 02:00 |
EQS-Adhoc: Newron: Positive Topline-Ergebnisse der potenziell zulassungsrelevan…
|
German | 13.3 KB | ||
| 2024-04-17 02:00 |
EQS-Adhoc: Newron vermeldet die Resultate der Generalversammlung 2024
|
German | 2.2 KB | ||
| 2024-04-08 02:00 |
EQS-News: Data from Newron’s study 014/015 and an evenamide clinical developmen…
|
English | 15.8 KB | ||
| 2024-04-08 02:00 |
EQS-News: Newron präsentiert Daten der Studie 014/015 und Pläne für weitere kli…
|
German | 18.2 KB | ||
| 2024-03-19 01:00 |
EQS-Adhoc: Newron gibt Geschäftsergebnisse 2023 und Ausblick 2024 bekannt
|
German | 22.1 KB | ||
| 2024-03-19 01:00 |
EQS-News: Newron presents 2023 financial results and provides 2024 outlook
|
English | 31.6 KB | ||
| 2024-03-19 01:00 |
EQS-News: Newron gibt Geschäftsergebnisse 2023 und Ausblick 2024 bekannt
|
German | 36.7 KB | ||
| 2024-03-15 01:00 |
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to…
|
English | 9.5 KB | ||
| 2024-03-15 01:00 |
EQS-News: Newron gibt Vereinbarung mit der Europäischen Investitionsbank (EIB) …
|
German | 11.0 KB | ||
| 2024-03-15 01:00 |
EQS-Adhoc: Newron gibt Vereinbarung mit der Europäischen Investitionsbank (EIB…
|
German | 8.8 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Newron Pharmaceuticals S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
